NYSE:MRKMerck & Co., Inc. Stock Price, Forecast & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRK stock has decreased by 0.7% and is now trading at $78.72. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Friday, July 31st 2020. View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. will be holding an earnings conference call on Friday, July 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings data on Tuesday, April, 28th. The company reported $1.50 EPS for the quarter, topping the consensus estimate of $1.34 by $0.16. The firm earned $12.06 billion during the quarter, compared to analyst estimates of $11.46 billion. Merck & Co., Inc. had a return on equity of 52.46% and a net margin of 21.10%. The business's quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.22 earnings per share. View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. announced a quarterly dividend on Tuesday, May 26th. Shareholders of record on Monday, June 15th will be given a dividend of $0.61 per share on Tuesday, July 7th. This represents a $2.44 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date of this dividend is Friday, June 12th. View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. announced that its board has initiated a share repurchase plan on Thursday, October 25th 2018, which permits the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to buy up to 5.1% of its stock through open market purchases. Stock buyback plans are often an indication that the company's board of directors believes its stock is undervalued.

Merck & Co., Inc. updated its FY 2020 Pre-Market earnings guidance on Tuesday, April, 28th. The company provided EPS guidance of 5.17-5.37 for the period, compared to the Thomson Reuters consensus estimate of $5.56. The company issued revenue guidance of $46.1-48.1 billion, compared to the consensus revenue estimate of $48.72 billion.

13 equities research analysts have issued twelve-month target prices for Merck & Co., Inc.'s shares. Their forecasts range from $89.00 to $105.00. On average, they expect Merck & Co., Inc.'s share price to reach $94.15 in the next year. This suggests a possible upside of 19.6% from the stock's current price. View analysts' price targets for Merck & Co., Inc..

News coverage about MRK stock has been trending negative on Tuesday, according to InfoTrie. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Merck & Co., Inc. earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Merck & Co., Inc..

Merck & Co., Inc. saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 14,560,000 shares, a decline of 7.9% from the June 15th total of 15,810,000 shares. Based on an average trading volume of 11,610,000 shares, the days-to-cover ratio is currently 1.3 days. Currently, 0.6% of the company's stock are sold short. View Merck & Co., Inc.'s Current Options Chain.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Walt Disney (DIS), Cisco Systems (CSCO), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), AbbVie (ABBV) and Exxon Mobil (XOM).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by a variety of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.03%), Cacti Asset Management LLC (0.03%), Park National Corp OH (0.01%), Private Asset Management Inc. (0.01%), Woodstock Corp (0.00%) and Fulton Bank N. A. (0.00%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks. View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Cacti Asset Management LLC, HNP Capital LLC, Municipal Employees Retirement System of Michigan, Park National Corp OH, M&R Capital Management Inc., Cullinan Associates Inc., First Financial Bank Trust Division, and Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Julie L Gerberding, Richard R Deluca, and Wendell P Weeks. View insider buying and selling activity for Merck & Co., Inc..

MRK stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Fulton Bank N. A., Watchman Group Inc., Red Spruce Capital LLC, Cox Capital Mgt LLC, Robecosam AG, OmniStar Financial Group Inc., and Groesbeck Investment Management Corp NJ. View insider buying and selling activity for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $78.72.

Merck & Co., Inc. has a market capitalization of $198.70 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]